The latest update is out from Immutep ( (IMMP) ).
Immutep Limited reported its half-year financial results for the period ending December 31, 2024, showing a 77% increase in total revenue and other income, amounting to A$7,276,004. Despite this, the company experienced a 5% increase in net loss, totaling A$22,377,429, primarily due to higher R&D and intellectual property expenses. The company continues to advance its lead product candidate, eftilagimod alpha, through a Phase III clinical trial for non-small cell lung cancer, alongside other trials for head and neck squamous cell carcinoma and metastatic breast cancer. The commencement of the TACTI-004 trial marks Immutep’s transition to a Phase III stage biotech company, highlighting its ongoing progress and potential impact on the industry.
More about Immutep
Immutep Limited is a clinical stage biotechnology company focused on developing novel Lymphocyte Activation Gene-3 (LAG3) related immunotherapies for cancer and autoimmune diseases. It is a pioneer in LAG-3 therapeutics, with a diversified product portfolio aimed at stimulating the immune response to combat cancer or suppress it to treat autoimmune conditions. The company is listed on the Australian Securities Exchange and NASDAQ.
YTD Price Performance: -14.03%
Average Trading Volume: 103,754
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $280M
For an in-depth examination of IMMP stock, go to TipRanks’ Stock Analysis page.